scout
Opinion|Videos|September 16, 2024

AE Management with Atezolizumab + Bevacizumab

Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B.

Episodes in this series

Video content above is prompted by the following:

  • Please share your thoughts on the data based on baseline varices from IMbrave 150.
  • Concerning safety data, is this in line with you what you see in practice for the vp4 and baseline varices?
  • How do you currently manage AEs seen in practice?
  • Please share your thoughts on the data based on Child-Pugh A vs B for IMbrave 150.
  • How do you consider immunotherapy to be different for Child-Pugh A vs B?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content